Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/09/2017 | 09:28am CET

Hikma Pharmaceuticals Plc (>> Hikma Pharmaceuticals) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's (>> GlaxoSmithKline) popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

Hikma Pharmaceuticals Plc (>> Hikma Pharmaceuticals) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's (>> GlaxoSmithKline) popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

The dispute between the Jordan-based firm, its partner Vectura (>> Vectura Group PLC) and the U.S FDA delays any eventual approval of the generic version of the drug.

Shares of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.

Hikma, which makes and markets branded and non-branded generic and injectable drugs, said it expected revenue of around $600 million and a core operating margin in the low single-digits from its generics business.

In August it had lowered its generics revenue guidance by $50 million to about $620 million citing higher pricing pressures in the industry, having slashed it to $670 million from an initial $800 million last November.

The company, that has been hit by higher price erosion levels than the rest of the industry, has been re-negotiating its contracts with suppliers and third-party vendors to cut costs to try to boost profitability.

"We expect these market conditions to persist in 2018 and are actively pursuing new commercial opportunities and focussing on the execution of our pipeline to help offset continuing price erosion across the industry," it said in a statement.

The company, which cut its full-year guidance in May to the range of $2 billion-$2.1 billion from $2.2 billion, said in August that it expected 2017 revenue to be at the lower end of the range at $2 billion.

Hikma reiterated its 2017 revenue expectations on Thursday.

Earlier this month, Israeli-based Teva Pharmaceutical (>> Teva Pharmaceutical Industries Limited), the world's biggest generics drugmaker, said it would miss 2017 profit forecasts citing falling prices of generics in the U.S. market and weakening sales of its multiple sclerosis drug.

Hikma's lower guidance in May followed a decision by U.S. regulators not to approve its generic version of GlaxoSmithKline Plc's blockbuster lung drug Advair, citing "major" issues with the application.

Hikma said it expected the dispute process with the FDA to be completed in the first quarter of 2018.

(Reporting by Justin George Varghese in Bengaluru and Ben Hirschler in London; editing by Jason Neely and Keith Weir)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
01/19 En route to Davos, Macron makes Versailles the place to be
01/19 GLAXOSMITHKLINE : 19.8% Potential Upside Indicated by Liberum Capital
01/19 GLAXOSMITHKLINE : UK-based drugmaker GlaxoSmithKline mulls Kenya staff cuts
01/19 GLAXOSMITHKLINE : Findings from GlaxoSmithKline plc Provides New Data about Comb..
01/19 GLAXOSMITHKLINE : Recent Findings from GlaxoSmithKline plc Has Provided New Info..
01/19 At AstraZeneca, fewer drug projects bring big productivity jump
01/18 GLAXOSMITHKLINE EYES $1.7B BID FOR R : report
01/17 ASPEN PHARMACARE : Drugmaker GSK cuts back in Africa to hone emerging markets mo..
01/15 GLAXOSMITHKLINE : National Institutes of Health - Brian Berridge tapped to manag..
01/13 GLAXOSMITHKLINE : Brian Berridge Tapped to Manage National Toxicology Program
More news
News from SeekingAlpha
01/21 U.S. flu season is getting worse
01/20 STOCKS TO WATCH : Earnings Season Hits Higher Gear
01/18 Big Biopharma in the red in early trade
01/17 NOVO NORDISK : Don't Spoil The Ablynx Acquisition
01/17 NeuroMetrix inks deal with Glaxo for Quell ex-U.S.; shares ahead 68% premarke..
Financials ( GBP)
Sales 2017 30 076 M
EBIT 2017 8 296 M
Net income 2017 3 592 M
Debt 2017 13 840 M
Yield 2017 5,89%
P/E ratio 2017 19,34
P/E ratio 2018 15,29
EV / Sales 2017 2,70x
EV / Sales 2018 2,66x
Capitalization 67 329 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 31
Average target price 15,5  GBP
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE2.68%93 277
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132